Research programme: ion-channel modulators - Asana BioSciencesAlternative Names: ASN008; ASN009
Latest Information Update: 02 Dec 2015
At a glance
- Originator Asana BioSciences
- Mechanism of Action Purinergic P2X3 receptor antagonists; Sodium channel antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Genitourinary disorders; Pain; Pruritus
Most Recent Events
- 02 Dec 2015 Preclinical trials in Genitourinary disorders in USA (PO)
- 02 Dec 2015 Preclinical trials in Pruritus in USA (Topical)
- 02 Dec 2015 Preclinical trials in Pain in USA (Topical)